This document summarizes measles outbreak data reported to the World Health Organization from countries in the European Region between 2016 and 2018. It finds that Ukraine had the highest number of measles cases in 2018 at over 53,000, while incidence was highest in Ukraine, Serbia, and Georgia. Overall cases rose sharply from around 5,000 in 2016 to over 82,000 in 2018. The data is broken down by month, country, age group, and vaccination status to analyze trends and inform response.
Reported measles cases for the period November 2020—October 2021 (data as of 02 December 2021).A monthly summary of the epidemiological data on selected vaccine-preventable diseases in the WHO European Region
Reported measles cases for the period November 2020—October 2021 (data as of 02 December 2021).A monthly summary of the epidemiological data on selected vaccine-preventable diseases in the WHO European Region
Opendatabay - Open Data Marketplace.pptxOpendatabay
Opendatabay.com unlocks the power of data for everyone. Open Data Marketplace fosters a collaborative hub for data enthusiasts to explore, share, and contribute to a vast collection of datasets.
First ever open hub for data enthusiasts to collaborate and innovate. A platform to explore, share, and contribute to a vast collection of datasets. Through robust quality control and innovative technologies like blockchain verification, opendatabay ensures the authenticity and reliability of datasets, empowering users to make data-driven decisions with confidence. Leverage cutting-edge AI technologies to enhance the data exploration, analysis, and discovery experience.
From intelligent search and recommendations to automated data productisation and quotation, Opendatabay AI-driven features streamline the data workflow. Finding the data you need shouldn't be a complex. Opendatabay simplifies the data acquisition process with an intuitive interface and robust search tools. Effortlessly explore, discover, and access the data you need, allowing you to focus on extracting valuable insights. Opendatabay breaks new ground with a dedicated, AI-generated, synthetic datasets.
Leverage these privacy-preserving datasets for training and testing AI models without compromising sensitive information. Opendatabay prioritizes transparency by providing detailed metadata, provenance information, and usage guidelines for each dataset, ensuring users have a comprehensive understanding of the data they're working with. By leveraging a powerful combination of distributed ledger technology and rigorous third-party audits Opendatabay ensures the authenticity and reliability of every dataset. Security is at the core of Opendatabay. Marketplace implements stringent security measures, including encryption, access controls, and regular vulnerability assessments, to safeguard your data and protect your privacy.
Chatty Kathy - UNC Bootcamp Final Project Presentation - Final Version - 5.23...John Andrews
SlideShare Description for "Chatty Kathy - UNC Bootcamp Final Project Presentation"
Title: Chatty Kathy: Enhancing Physical Activity Among Older Adults
Description:
Discover how Chatty Kathy, an innovative project developed at the UNC Bootcamp, aims to tackle the challenge of low physical activity among older adults. Our AI-driven solution uses peer interaction to boost and sustain exercise levels, significantly improving health outcomes. This presentation covers our problem statement, the rationale behind Chatty Kathy, synthetic data and persona creation, model performance metrics, a visual demonstration of the project, and potential future developments. Join us for an insightful Q&A session to explore the potential of this groundbreaking project.
Project Team: Jay Requarth, Jana Avery, John Andrews, Dr. Dick Davis II, Nee Buntoum, Nam Yeongjin & Mat Nicholas
As Europe's leading economic powerhouse and the fourth-largest hashtag#economy globally, Germany stands at the forefront of innovation and industrial might. Renowned for its precision engineering and high-tech sectors, Germany's economic structure is heavily supported by a robust service industry, accounting for approximately 68% of its GDP. This economic clout and strategic geopolitical stance position Germany as a focal point in the global cyber threat landscape.
In the face of escalating global tensions, particularly those emanating from geopolitical disputes with nations like hashtag#Russia and hashtag#China, hashtag#Germany has witnessed a significant uptick in targeted cyber operations. Our analysis indicates a marked increase in hashtag#cyberattack sophistication aimed at critical infrastructure and key industrial sectors. These attacks range from ransomware campaigns to hashtag#AdvancedPersistentThreats (hashtag#APTs), threatening national security and business integrity.
🔑 Key findings include:
🔍 Increased frequency and complexity of cyber threats.
🔍 Escalation of state-sponsored and criminally motivated cyber operations.
🔍 Active dark web exchanges of malicious tools and tactics.
Our comprehensive report delves into these challenges, using a blend of open-source and proprietary data collection techniques. By monitoring activity on critical networks and analyzing attack patterns, our team provides a detailed overview of the threats facing German entities.
This report aims to equip stakeholders across public and private sectors with the knowledge to enhance their defensive strategies, reduce exposure to cyber risks, and reinforce Germany's resilience against cyber threats.
Show drafts
volume_up
Empowering the Data Analytics Ecosystem: A Laser Focus on Value
The data analytics ecosystem thrives when every component functions at its peak, unlocking the true potential of data. Here's a laser focus on key areas for an empowered ecosystem:
1. Democratize Access, Not Data:
Granular Access Controls: Provide users with self-service tools tailored to their specific needs, preventing data overload and misuse.
Data Catalogs: Implement robust data catalogs for easy discovery and understanding of available data sources.
2. Foster Collaboration with Clear Roles:
Data Mesh Architecture: Break down data silos by creating a distributed data ownership model with clear ownership and responsibilities.
Collaborative Workspaces: Utilize interactive platforms where data scientists, analysts, and domain experts can work seamlessly together.
3. Leverage Advanced Analytics Strategically:
AI-powered Automation: Automate repetitive tasks like data cleaning and feature engineering, freeing up data talent for higher-level analysis.
Right-Tool Selection: Strategically choose the most effective advanced analytics techniques (e.g., AI, ML) based on specific business problems.
4. Prioritize Data Quality with Automation:
Automated Data Validation: Implement automated data quality checks to identify and rectify errors at the source, minimizing downstream issues.
Data Lineage Tracking: Track the flow of data throughout the ecosystem, ensuring transparency and facilitating root cause analysis for errors.
5. Cultivate a Data-Driven Mindset:
Metrics-Driven Performance Management: Align KPIs and performance metrics with data-driven insights to ensure actionable decision making.
Data Storytelling Workshops: Equip stakeholders with the skills to translate complex data findings into compelling narratives that drive action.
Benefits of a Precise Ecosystem:
Sharpened Focus: Precise access and clear roles ensure everyone works with the most relevant data, maximizing efficiency.
Actionable Insights: Strategic analytics and automated quality checks lead to more reliable and actionable data insights.
Continuous Improvement: Data-driven performance management fosters a culture of learning and continuous improvement.
Sustainable Growth: Empowered by data, organizations can make informed decisions to drive sustainable growth and innovation.
By focusing on these precise actions, organizations can create an empowered data analytics ecosystem that delivers real value by driving data-driven decisions and maximizing the return on their data investment.
Data Centers - Striving Within A Narrow Range - Research Report - MCG - May 2...pchutichetpong
M Capital Group (“MCG”) expects to see demand and the changing evolution of supply, facilitated through institutional investment rotation out of offices and into work from home (“WFH”), while the ever-expanding need for data storage as global internet usage expands, with experts predicting 5.3 billion users by 2023. These market factors will be underpinned by technological changes, such as progressing cloud services and edge sites, allowing the industry to see strong expected annual growth of 13% over the next 4 years.
Whilst competitive headwinds remain, represented through the recent second bankruptcy filing of Sungard, which blames “COVID-19 and other macroeconomic trends including delayed customer spending decisions, insourcing and reductions in IT spending, energy inflation and reduction in demand for certain services”, the industry has seen key adjustments, where MCG believes that engineering cost management and technological innovation will be paramount to success.
MCG reports that the more favorable market conditions expected over the next few years, helped by the winding down of pandemic restrictions and a hybrid working environment will be driving market momentum forward. The continuous injection of capital by alternative investment firms, as well as the growing infrastructural investment from cloud service providers and social media companies, whose revenues are expected to grow over 3.6x larger by value in 2026, will likely help propel center provision and innovation. These factors paint a promising picture for the industry players that offset rising input costs and adapt to new technologies.
According to M Capital Group: “Specifically, the long-term cost-saving opportunities available from the rise of remote managing will likely aid value growth for the industry. Through margin optimization and further availability of capital for reinvestment, strong players will maintain their competitive foothold, while weaker players exit the market to balance supply and demand.”
Measles and Rubella monthly update for the WHO Europes Region January 2019
1. Measles and rubella monthly update
for the WHO European Region
Data as of 1 February 2019
Vaccine-preventable Diseases and Immunization programme
Division of Health Emergencies and Communicable Diseases
5. Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe directly or via ECDC/TESSy data as of 1 February 2019
1087
1466
2193
2203
2256
2517
2913
2919
5076
53218
0 10000 20000 30000 40000 50000 60000
Romania
Albania
Greece
Georgia
Russian Federation
Italy
France
Israel
Serbia
Ukraine
Number of cases
Ten countries with the highest numbers of measles cases in the WHO European
Region, January–December 2018
Out of 82 596 measles cases reported for 2018, 75 848 (92%)
cases were reported by these 10 countries.
5
6. Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe directly or via ECDC/TESSy data as of 1 February 2019
367
518
651
702
897
936
1067
4782
5393
9072
0 1000 2000 3000 4000 5000 6000 7000 8000 9000 10000
Belgium
France
Tajikistan
Serbia
Russian Federation
Germany
Greece
Ukraine
Italy
Romania
Number of cases
Ten countries with the highest numbers of measles cases in the WHO European
Region, January–December 2017
6
Out of 25 863 measles cases reported for 2017, 24 385 (94%)
cases were reported by these 10 countries.
7. Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe directly or via ECDC/TESSy data as of 1 February 2019
Measles cases by month in the WHO European Region, 2016–2018
7
Criteria for date of case inclusion may differ in accordance with Member States’ surveillance systems.
0
2000
4000
6000
8000
10000
12000
14000
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2016
(n=5273)
2017
(n=25863)
2018
(n=82596)
Numberofcases
Month
Lab confirmed Epi linked Clinically compatible
8. Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe directly or via ECDC/TESSy data as of 1 February 2019
Measles cases and incidence by age group and vaccination status in the WHO
European Region, January–December 2018*
8
Population source: United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects: The 2017 Revision.
*Age was unknown for 7 cases.
596
319
235
182 164
114
29
0
100
200
300
400
500
600
700
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
<1
(n=6441)
1–4
(n=14371)
5–9
(n=13292)
10–14
(n=9694)
15–19
(n=8409)
20–29
(n=13383)
30+
(n=16998)
Incidencepermillionpopulation
Numberofcases
Age group (years)
0 dose 1 dose 2+ doses Unknown Incidence
9. Ten countries with the highest numbers
of measles cases in the WHO European Region
for the period January–December 2018
(in alphabetical order)
9
10. Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe directly or via ECDC/TESSy data as of 1 February 2019
Albania: measles cases by month, 2016–2018
10
Criteria for date of case inclusion may differ in accordance with Member States’ surveillance systems.
0
50
100
150
200
250
300
350
400
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2016
(n=0)
2017
(n=12)
2018
(n=1466)
Numberofcases
Month
Lab confirmed Epi linked Clinically compatible
11. Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe directly or via ECDC/TESSy data as of 1 February 2019
Albania: measles cases and incidence by age group and vaccination status,
January–December 2018
11
Population source: United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects: The 2017 Revision.
8014
1488
286 430
1170
605
194
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
0
50
100
150
200
250
300
350
400
<1
(n=270)
1–4
(n=208)
5–9
(n=46)
10–14
(n=72)
15–19
(n=256)
20–29
(n=273)
30+
(n=341)
Incidencepermillionpopulation
Numberofcases
Age group (years)
0 dose 1 dose 2+ doses Unknown Incidence
12. Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe directly or via ECDC/TESSy data as of 1 February 2019
France: measles cases by month, 2016–2018
12
Criteria for date of case inclusion may differ in accordance with Member States’ surveillance systems.
0
100
200
300
400
500
600
700
800
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2016
(n=79)
2017
(n=518)
2018
(n=2913)
Numberofcases
Month
Lab confirmed Epi linked Clinically compatible
13. Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe directly or via ECDC/TESSy data as of 1 February 2019
France: measles cases and incidence by age group and vaccination status,
January–December 2018*
13
Population source: United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects: The 2017 Revision.
*Age was unknown for 1 case.
374
201
74
88 87
63
13
0
50
100
150
200
250
300
350
400
0
100
200
300
400
500
600
700
<1
(n=283)
1–4
(n=614)
5–9
(n=290)
10–14
(n=349)
15–19
(n=341)
20–29
(n=479)
30+
(n=556)
Incidencepermillionpopulation
Numberofcases
Age group (years)
0 dose 1 dose 2+ doses Unknown Incidence
14. Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe directly or via ECDC/TESSy data as of 1 February 2019
Georgia: measles cases by month, 2016–2018
14
Criteria for date of case inclusion may differ in accordance with Member States’ surveillance systems.
0
100
200
300
400
500
600
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2016
(n=14)
2017
(n=96)
2018
(n=2203)
Numberofcases
Month
Lab confirmed Epi linked Clinically compatible
15. Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe directly or via ECDC/TESSy data as of 1 February 2019
Georgia: measles cases and incidence by age group and vaccination status,
January–December 2018
15
Population source: United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects: The 2017 Revision.
4635
1451
486
750 744
1121
258
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
0
100
200
300
400
500
600
700
<1
(n=220)
1–4
(n=309)
5–9
(n=130)
10–14
(n=173)
15–19
(n=158)
20–29
(n=591)
30+
(n=622)
Incidencepermillionpopulation
Numberofcases
Age group (years)
0 dose 1 dose 2+ doses Unknown Incidence
16. Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe directly or via ECDC/TESSy data as of 1 February 2019
Greece: measles cases by month, 2016–2018
16
Criteria for date of case inclusion may differ in accordance with Member States’ surveillance systems.
0
100
200
300
400
500
600
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2016
(n=0)
2017
(n=1067)
2018
(n=2193)
Numberofcases
Month
Lab confirmed Epi linked Clinically compatible
17. Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe directly or via ECDC/TESSy data as of 1 February 2019
Greece: measles cases and incidence by age group and vaccination status,
January–December 2018
17
Population source: United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects: The 2017 Revision.
2780
1349
544 484
230 175
71
0
500
1000
1500
2000
2500
3000
0
100
200
300
400
500
600
<1
(n=234)
1–4
(n=496)
5–9
(n=298)
10–14
(n=277)
15–19
(n=127)
20–29
(n=201)
30+
(n=560)
Incidencepermillionpopulation
Numberofcases
Age group (years)
0 dose 1 dose 2+ doses Unknown Incidence
18. Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe directly or via ECDC/TESSy data as of 1 February 2019
Israel: measles cases by month, 2016–2018
18
Criteria for date of case inclusion may differ in accordance with Member States’ surveillance systems.
0
100
200
300
400
500
600
700
800
900
1000
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2016
(n=10)
2017
(n=16)
2018
(n=2919)
Numberofcases
Month
Lab confirmed Epi linked Clinically compatible
19. Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe directly or via ECDC/TESSy data as of 1 February 2019
Israel: measles cases and incidence by age group and vaccination status,
January–December 2018
19
Population source: United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects: The 2017 Revision.
3131
1258
581
422
251 179 100
0
500
1000
1500
2000
2500
3000
3500
0
100
200
300
400
500
600
700
800
900
<1
(n=506)
1–4
(n=847)
5–9
(n=464)
10–14
(n=301)
15–19
(n=164)
20–29
(n=210)
30+
(n=427)
Incidencepermillionpopulation
Numberofcases
Age group (years)
0 dose 1 dose 2+ doses Unknown Incidence
20. Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe directly or via ECDC/TESSy data as of 1 February 2019
Italy: measles cases by month, 2016–2018
20
Criteria for date of case inclusion may differ in accordance with Member States’ surveillance systems.
0
200
400
600
800
1000
1200
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2016
(n=861)
2017
(n=5393)
2018
(n=2517)
Numberofcases
Month
Lab confirmed Epi linked Clinically compatible
21. Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe directly or via ECDC/TESSy data as of 1 February 2019
Italy: measles cases and incidence by age group and vaccination status,
January–December 2018*
21
Population source: United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects: The 2017 Revision.
*Age was unknown for 2 cases.
334
166
33 35
54
137
21
0
50
100
150
200
250
300
350
400
0
100
200
300
400
500
600
700
800
900
1000
<1
(n=160)
1–4
(n=325)
5–9
(n=90)
10–14
(n=100)
15–19
(n=151)
20–29
(n=805)
30+
(n=884)
Incidencepermillionpopulation
Numberofcases
Age group (years)
0 dose 1 dose 2+ doses Unknown Incidence
22. Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe directly or via ECDC/TESSy data as of 1 February 2019
Romania: measles cases by month, 2016–2018
22
Criteria for date of case inclusion may differ in accordance with Member States’ surveillance systems.
0
200
400
600
800
1000
1200
1400
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2016
(n=2432)
2017
(n=9072)
2018
(n=1087)
Numberofcases
Month
Lab confirmed Epi linked Clinically compatible
23. Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe directly or via ECDC/TESSy data as of 1 February 2019
Romania: measles cases and incidence by age group and vaccination status,
January–December 2018
23
Population source: United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects: The 2017 Revision.
1707
449
143 100 51 23 6
0
200
400
600
800
1000
1200
1400
1600
1800
0
50
100
150
200
250
300
350
400
<1
(n=314)
1–4
(n=335)
5–9
(n=144)
10–14
(n=105)
15–19
(n=53)
20–29
(n=54)
30+
(n=82)
Incidencepermillionpopulation
Numberofcases
Age group (years)
0 dose 1 dose 2+ doses Unknown Incidence
24. Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe directly or via ECDC/TESSy data as of 1 February 2019
Russian Federation: measles cases by month, 2016–2018
24
Criteria for date of case inclusion may differ in accordance with Member States’ surveillance systems.
0
50
100
150
200
250
300
350
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2016
(n=180)
2017
(n=897)
2018
(n=2256)
Numberofcases
Month
Lab confirmed Epi linked Clinically compatible
25. Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe directly or via ECDC/TESSy data as of 1 February 2019
Russian Federation: measles cases and incidence by age group and vaccination
status, January–December 2018
25
Population source: United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects: The 2017 Revision.
122
75
27
22 19 17
7
0
20
40
60
80
100
120
140
0
100
200
300
400
500
600
700
<1
(n=214)
1–4
(n=569)
5–9
(n=241)
10–14
(n=163)
15–19
(n=127)
20–29
(n=298)
30+
(n=644)
Incidencepermillionpopulation
Numberofcases
Age group (years)
0 dose 1 dose 2+ doses Unknown Incidence
26. Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe directly or via ECDC/TESSy data as of 1 February 2019
Serbia: measles cases by month, 2016–2018
26
Criteria for date of case inclusion may differ in accordance with Member States’ surveillance systems.
0
200
400
600
800
1000
1200
1400
1600
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2016
(n=14)
2017
(n=702)
2018
(n=5076)
Numberofcases
Month
Lab confirmed Epi linked Clinically compatible
27. Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe directly or via ECDC/TESSy data as of 1 February 2019
Serbia: measles cases and incidence by age group and vaccination status,
January–December 2018*
27
Population source: United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects: The 2017 Revision.
*Age was unknown for 3 cases.
4408
1885
401 275
445
630 474
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
0
500
1000
1500
2000
2500
3000
<1
(n=410)
1–4
(n=699)
5–9
(n=188)
10–14
(n=137)
15–19
(n=235)
20–29
(n=715)
30+
(n=2689)
Incidencepermillionpopulation
Numberofcases
Age group (years)
0 dose 1 dose 2+ doses Unknown Incidence
28. Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe directly or via ECDC/TESSy data as of 1 February 2019
Ukraine: measles cases by month, 2016–2018
28
Criteria for date of case inclusion may differ in accordance with Member States’ surveillance systems.
0
2000
4000
6000
8000
10000
12000
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2016
(n=90)
2017
(n=4782)
2018
(n=53218)
Numberofcases
Month
Lab confirmed Epi linked Clinically compatible
29. Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe directly or via ECDC/TESSy data as of 1 February 2019
Ukraine: measles cases and incidence by age group and vaccination status,
January–December 2018
29
Population source: United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects: The 2017 Revision.
6091
4500 4421
3451 3272
1629
292
0
1000
2000
3000
4000
5000
6000
7000
0
2000
4000
6000
8000
10000
12000
<1
(n=2666)
1–4
(n=8393)
5–9
(n=10863)
10–14
(n=7551)
15–19
(n=6305)
20–29
(n=8743)
30+
(n=8697)
Incidencepermillionpopulation
Numberofcases
Age group (years)
0 dose 1 dose 2+ doses Unknown Incidence
33. Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe directly or via ECDC/TESSy data as of 1 February 2019
16
23
57
235
450
0 50 100 150 200 250 300 350 400 450 500
Turkey
Italy
Germany
Ukraine
Poland
Number of cases
Five countries with the highest numbers of rubella cases in the WHO European
Region, January–December 2018
33
Out of 850 rubella cases reported for 2018,781 (92%)
cases were reported by these 5 countries.
34. Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe directly or via ECDC/TESSy data as of 1 February 2019
9
41
68
74
476
0 50 100 150 200 250 300 350 400 450 500
Romania
Austria
Italy
Germany
Poland
Number of cases
Five countries with the highest numbers of rubella cases in the WHO European
Region, January–December 2017
34
Out of 702 rubella cases reported for 2017,668 (95%)
cases were reported by these 5 countries.
35. Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe directly or via ECDC/TESSy data as of 1 February 2019
Rubella cases by month in the WHO European Region, 2016–2018
35
0
20
40
60
80
100
120
140
160
180
200
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2016
(n=1322)
2017
(n=702)
2018
(n=850)
Numberofcases
Month
Lab confirmed Epi linked Clinically compatible
Criteria for date of case inclusion may differ in accordance with Member States’ surveillance systems.
36. Five countries with the highest numbers
of rubella cases in the WHO European Region
for the period January–December 2018
(in alphabetical order)
36
37. Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe directly or via ECDC/TESSy data as of 1 February 2019
Germany: rubella cases by month, 2016–2018
37
0
2
4
6
8
10
12
14
16
18
20
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2016
(n=96)
2017
(n=74)
2018
(n=57)
Numberofcases
Month
Lab confirmed Epi linked Clinically compatible
Criteria for date of case inclusion may differ in accordance with Member States’ surveillance systems.
38. Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe directly or via ECDC/TESSy data as of 1 February 2019
Italy: rubella cases by month, 2016–2018
38
Criteria for date of case inclusion may differ in accordance with Member States’ surveillance systems.
0
2
4
6
8
10
12
14
16
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2016
(n=30)
2017
(n=68)
2018
(n=23)
Numberofcases
Month
Lab confirmed Epi linked Clinically compatible
39. Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe directly or via ECDC/TESSy data as of 1 February 2019
Poland: rubella cases by month, 2016–2018
39
0
20
40
60
80
100
120
140
160
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2016
(n=1105)
2017
(n=476)
2018
(n=450)
Numberofcases
Month
Lab confirmed Epi linked Clinically compatible
Criteria for date of case inclusion may differ in accordance with Member States’ surveillance systems.
40. Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe directly or via ECDC/TESSy data as of 1 February 2019
Turkey: rubella cases by month, 2016–2018
40
Criteria for date of case inclusion may differ in accordance with Member States’ surveillance systems.
0
1
2
3
4
5
6
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2016
(n=0)
2017
(n=2)
2018
(n=16)
Numberofcases
Month
Lab confirmed Epi linked Clinically compatible
41. Data source: Monthly aggregated and case-based data reported by Member States to WHO/Europe directly or via ECDC/TESSy data as of 1 February 2019
Ukraine: rubella cases by month, 2018
41
*Rubella cases reporting began January 2018.
0
5
10
15
20
25
30
35
40
45
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2016* 2017* 2018
(n=235)
Numberofcases
Month
Lab confirmed Epi linked Clinically compatible
Criteria for date of case inclusion may differ in accordance with Member States’ surveillance systems.
Discarded case: a suspected case that was investigated and discarded, either through negative results of adequate laboratory testing for measles and rubella or by an epidemiological link to a laboratory-confirmed case of another disease; in addition, IgM-positive cases in recent vaccine recipients can be discarded if they meet all of the following criteria:
history of vaccination with relevant vaccine 7 days to 6 weeks prior to specimen collection;
onset of rash 7−14 days after vaccination;
no evidence of virus transmission revealed by active search in community;
no history of travel to areas in which the virus is known to be circulating.